Navigation Links
Cepheid Reports Fourth Quarter And Full Year 2012 Results
Date:1/24/2013

>All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

FINANCIAL TABLES FOLLOW  CEPHEID 

 

CONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF OPERATIONS(in thousands, except per share data)

 Three Months Ended December 31, Years Ended
December 31, 2012201120122011Revenues:System sales

$  14,101$  20,371$   55,447$  61,948Reagent and disposable sales

75,55756,576266,101203,576Total product sales

89,65876,947321,548265,524Other revenues

2,7753,1679,66412,051Total revenues 

92,43380,114331,212277,575Costs and operating expenses:Cost of product sales 

42,89638,632153,365122,840Collaboration profit sharing 

1,4161,5827,1834,863Research and development

17,29916,65071,67359,362Sales and marketing

16,29414,49061,90750,691General and administrative

9,47010,15343,29836,004Litigation settlement

--15,110-Total costs and operating expenses 

87,37581,507352,536273,760Income (loss) from operations 

5,058(1,393)(21,324)3,815Other income (expense), net

241(506)(4)(1,143)Income (loss) before income taxes

5,299(1,899)(21,328)2,672Benefit from (provision for) income taxes

3452501,285(45)Net income (loss)

$
5,644$  (1,649)$ (20,043)$
2,627Basic net income (loss) per share 

$
.09$
(0.03)$
(0.30)$
.04Diluted net income (loss) per share 

$
.08$
(0.03)$
(0.30)$
.04Shares used in computing basic net income (loss) per share 

66,37064,11365,81262,735Shares used in computing diluted net income (loss) per share '/>"/>

SOURCE Cepheid
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Announces Executive Vice President Emerging Markets
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
7. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
8. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
9. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
10. Luminex Corporation Reports First Quarter 2012 Results
11. Hospira Reports First-Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and ... be able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of the ... steadfastly remains one of the most litigious industry ...
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... 16 BioVex Inc, a biotechnology,company developing clinical ... that the abstract describing the interim results,from its ... advanced metastatic,melanoma is now available at the American ... http://www.asco.org . A summary of the abstract,which describes ...
... Nektar,s Technology Enables First-Ever PEGylation of a Small Molecule with ... Demonstrated Therapeutic ... NKTR ) announced initial results today from a Phase ... activity in patients with refractory solid tumors. The study,also demonstrates ...
Cached Medicine Technology:BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5
(Date:4/17/2014)... targets that could be used to provide relief ... London made the discovery when researching how pain ... body. , Dr Marzia Malcangio said: "We have ... and our findings could help chemotherapy patients who ... side effect of some chemotherapy drugs (such as ...
(Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... School of Medicine (BUSM) have discovered that the ... experimental model. The findings, reported in the ... may lead to more effective treatments for alcoholism. ... the leading causes of illness and death in ... by limiting the productivity of workers and necessitating ...
(Date:4/17/2014)... scientists and their partners have found that their proprietary ... transmission of multiple sexually transmitted infections (STIs) in both ... virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded ... is effective against multiple strains of HIV, and has ... three viruses of at least eight hours prior to ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... Ill. , Feb. 10  Bright Hope, a Christian ... a $1 a day has been serving the ... in their partner network, they are strategically positioned to carry out ... OCHA reports estimate the number of Internally Displaced People (IDP,s) is ...
... TORRANCE, Calif. , Feb. 10 Henry Loubet ... join the Editorial Board of Payers & Providers , the ... California .  Keenan is the largest privately held insurance brokerage ... Providers delivers in-depth industry coverage, breaking news and a lively ...
... what factors may influence who contracts tuberculosis (TB)/HIV co-infection in ... of the disease, with the majority of cases now coming ... "HIV and Tuberculosis Co-infection Among Hispanics in Southern California: An ... the American Journal of Public Health. ...
... help explain osteoporosis among those with the eating disorder , ... disorder anorexia nervosa have excess levels of fat in their ... affects mainly young women, leads to extremely low body weight ... counterintuitive that an emaciated young woman with almost no subcutaneous ...
... , ... provides users easy access to validated asset documents and,drawings. , ... Orlando, FL (PRWEB) February 10, 2010 -- McLaren Software ... showcasing McLaren Services for Outlook at the ARC Advisory World Industry Forum in Orlando, Florida., ...
... , , Go Red For Women ... highlights , - Minority women,s awareness remains behind that of white ... heart attack warning signs or said they would dial 9-1-1 if ... women surveyed listed therapies to prevent cardiovascular disease that are not ...
Cached Medicine News:Health News:Haiti Relief: New Plans, New Hope 2Health News:Haiti Relief: New Plans, New Hope 3Health News:Keenan Chief Strategy Officer Selected to Join Editorial Board of Payers & Providers 2Health News:Keenan Chief Strategy Officer Selected to Join Editorial Board of Payers & Providers 3Health News:Burden of HIV/TB infections increasingly falling on Hispanic community 2Health News:With Anorexia, Body May Hoard Fat in Bones 2Health News:McLaren Software Extends the Reach of Asset Document Management Processes 2Health News:American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women 2Health News:American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women 3Health News:American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: